Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Proposes Changes To Target Hemoglobin Levels In ESRD Treatment

Executive Summary

CMS aims at “retiring” the floor hemoglobin level of 10 g/dL and lowering the target upper level to 11 g/dL in its proposed rule for the Medicare Part B prospective payment system for treatment of end-stage renal disease, a move that could apply more pressure to Amgen’s erythropoiesis-stimulating agents franchise.

You may also be interested in...



Kidney Disease: A Price-Sensitive Market But A Bundle Of Opportunity

Medicare’s bundling policy for drugs and services in dialysis has turned on the pricing pressure in kidney disease. The cost containment policies have negatively impacted sales of some drugs and put a spotlight on growing costs in chronic kidney disease and end-stage renal disease. Nonetheless, there is plenty of opportunity for new drugs that can address the area’s unmet medical need, especially if they can help to reduce broader health care spending. That will require demonstrating value to payors and providers, however, particularly for drugs that treat secondary conditions associated with kidney disease.

ESAs And Transfusions In Dialysis Patients: Watching For The Tipping Point

A study from the U.S. Renal Data System contributes to concerns that decreasing use of erythropoiesis-stimulating agents like Amgen’s Epogen in dialysis patients can lead to a significant increase in the need for blood transfusions.

ESRD Market Snapshot: The Price Has To Be Right

The market for kidney disease drugs is under pressure from Medicare cost containment policies. However, there is still room for new drugs – if they can demonstrate a cost-savings benefit.

Related Content

Topics

UsernamePublicRestriction

Register

PS053578

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel